Hosted on MSN1mon
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock
Earnings Estimate Revisions for Kyverna Therapeutics, Inc. This company is expected to earn -$3.29 per share for the fiscal year ending December 2024, which represents a year-over-year change of ...
Business Insider1mon
Kyverna Therapeutics, Inc. Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ ...